title: Quality of life and satisfaction of patients after full-face injections of abobotulinum toxin type A: A randomized, phase IV clinical trial.
abstract: BACKGROUND
  Although botulinum toxin type A (BoNT-A) has been used effectively and safely to reduce facial dynamic wrinkles, few studies assessed patients' quality of life and satisfaction after treatment.
  
  
  OBJECTIVE
  To assess the quality of life and satisfaction of patients treated with full-face injections of variable doses of abobotulinum toxin A (ABO).
  
  
  METHODS
  Ninety subjects were randomized into 3 different groups, receiving 120-165 U, 166-205 U and 206-250 U, respectively. WHOQOL- BREF and Satisfaction and Self-assessment Questionnaire (SSQ) were completed by subjects up to 6 months after treatment.
  
  
  RESULTS
  Most of the subjects were women (96.5%). For the physical domain in WHOQOL, a difference was observed between baseline and visit 2 (p = 0.036). There was no difference between groups for mean grades regarding amount of wrinkles, beauty, harmony and symmetry. However, there was a significant difference in the mean grades between visits. Patients' opinions also showed an improvement in their self-image up to four months after treatment, according to the self-grading.
  
  
  CONCLUSIONS
  The results presented in this study show improvements in patients' quality of life during the peak of action of BoNT-A treatment, regarding the physical aspect. In addition, patients reported good satisfaction after a full-face approach.
authors.forename: Doris
authors.initials: D
authors.lastname: Hexsel
authors.forename: Cristiano
authors.initials: C
authors.lastname: Brum
authors.forename: Manoela D
authors.initials: MD
authors.lastname: Porto
authors.forename: Mariana
authors.initials: M
authors.lastname: Soirefmann
authors.forename: Carolina
authors.initials: C
authors.lastname: Siega
authors.forename: Juliana
authors.initials: J
authors.lastname: Schilling-Souza
authors.forename: Ticiana C
authors.initials: TC
authors.lastname: Rodrigues
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D015595:Skin Aging / Q000187:drug effects*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA